Fate Therapeutics Inc

2
NAS:FATE (USA)  
$ 4.54 -0.225 (-4.71%) 10:08 PM EST
At Loss
P/B:
1.22
Market Cap:
$ 516.58M
Enterprise V:
$ 333.27M
Volume:
3.65M
Avg Vol (2M):
2.47M
Also Trade In:
Volume:
3.65M
At Loss
Avg Vol (2M):
2.47M

Business Description

Description
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Name Current Vs Industry Vs History
Cash-To-Debt 3.04
Equity-to-Asset 0.73
Debt-to-Equity 0.28
Debt-to-EBITDA -0.6
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.21
Distress
Grey
Safe
Beneish M-Score -4.16
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 3.31
9-Day RSI 12.99
14-Day RSI 23.36
6-1 Month Momentum % 267.22
12-1 Month Momentum % 6.27

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.48
Quick Ratio 8.48
Cash Ratio 8.06
Days Sales Outstanding 66.85

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4
Shareholder Yield % 1.08

Financials (Next Earnings Date:2024-05-03 Est.)

FATE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:FATE

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Fate Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 63.533
EPS (TTM) ($) -1.64
Beta 2.03
Volatility % 106.76
14-Day RSI 23.36
14-Day ATR ($) 0.48419
20-Day SMA ($) 6.16145
12-1 Month Momentum % 6.27
52-Week Range ($) 1.63 - 8.83
Shares Outstanding (Mil) 113.78

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Fate Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Fate Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Fate Therapeutics Inc Frequently Asked Questions

What is Fate Therapeutics Inc(FATE)'s stock price today?
The current price of FATE is $4.54. The 52 week high of FATE is $8.83 and 52 week low is $1.63.
When is next earnings date of Fate Therapeutics Inc(FATE)?
The next earnings date of Fate Therapeutics Inc(FATE) is 2024-05-03 Est..
Does Fate Therapeutics Inc(FATE) pay dividends? If so, how much?
Fate Therapeutics Inc(FATE) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1